1. Home
  2. ACCS vs XCUR Comparison

ACCS vs XCUR Comparison

Compare ACCS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACCS
  • XCUR
  • Stock Information
  • Founded
  • ACCS 1988
  • XCUR 2011
  • Country
  • ACCS United States
  • XCUR United States
  • Employees
  • ACCS N/A
  • XCUR N/A
  • Industry
  • ACCS Publishing
  • XCUR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACCS Consumer Discretionary
  • XCUR Health Care
  • Exchange
  • ACCS Nasdaq
  • XCUR Nasdaq
  • Market Cap
  • ACCS 46.2M
  • XCUR 46.0M
  • IPO Year
  • ACCS N/A
  • XCUR N/A
  • Fundamental
  • Price
  • ACCS $11.02
  • XCUR $6.09
  • Analyst Decision
  • ACCS Strong Buy
  • XCUR
  • Analyst Count
  • ACCS 1
  • XCUR 0
  • Target Price
  • ACCS $14.00
  • XCUR N/A
  • AVG Volume (30 Days)
  • ACCS 15.1K
  • XCUR 73.7K
  • Earning Date
  • ACCS 08-12-2025
  • XCUR 08-08-2025
  • Dividend Yield
  • ACCS N/A
  • XCUR N/A
  • EPS Growth
  • ACCS N/A
  • XCUR N/A
  • EPS
  • ACCS N/A
  • XCUR N/A
  • Revenue
  • ACCS $22,562,000.00
  • XCUR N/A
  • Revenue This Year
  • ACCS $3.05
  • XCUR N/A
  • Revenue Next Year
  • ACCS $15.47
  • XCUR N/A
  • P/E Ratio
  • ACCS N/A
  • XCUR N/A
  • Revenue Growth
  • ACCS 26.44
  • XCUR N/A
  • 52 Week Low
  • ACCS $7.79
  • XCUR $1.44
  • 52 Week High
  • ACCS $13.35
  • XCUR $36.00
  • Technical
  • Relative Strength Index (RSI)
  • ACCS 41.01
  • XCUR 37.05
  • Support Level
  • ACCS $10.80
  • XCUR $6.04
  • Resistance Level
  • ACCS $12.20
  • XCUR $7.06
  • Average True Range (ATR)
  • ACCS 0.68
  • XCUR 0.55
  • MACD
  • ACCS -0.11
  • XCUR -0.11
  • Stochastic Oscillator
  • ACCS 37.44
  • XCUR 4.48

About ACCS ACCESS Newswire Inc.

ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.

About XCUR Exicure Inc.

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Share on Social Networks: